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Introduction: Erlotinib (Tarceva®) has demonstrated a survival
benefit in unselected patients with advanced non-small cell lung
cancer (NSCLC) after failure of chemotherapy. Because not all
patients benefit from erlotinib, epidermal growth factor receptor
(EGFR) protein expression may provide a basis for selecting pa-
tients for treatment with this EGFR inhibitor.
Methods: Tumor samples from patients who participated in Na-
tional Institute of Canada Clinical Trials Group Study BR.21 were
assayed by immunohistochemistry using Dako EGFR pharmDx™
kits. EGFR expression was scored as proportion of tumor cells with
membrane staining, staining intensity, and combined proportion and
intensity scores. All possible cutpoints were examined to determine
whether EGFR protein expression status by immunohistochemistry
might be useful for predicting patient survival.
Results: Three hundred twenty-five patients had evaluable assay
results. The prognostic significance of EGFR protein expression was
modest. Patients with EGFR-positive tumors who received placebo
after failure of chemotherapy had slightly worse survival than
patients with EGFR-negative tumors; however, the differences were
not statistically significant for any cutpoint for any of the three
measures of EGFR protein expression. The treatment benefits from
erlotinib relative to placebo were greater for EGFR-positive patients
compared with EGFR-negative patients, but they were not signifi-
cantly different for any cutoff used to define EGFR positivity. Use
of very high cutpoints to define patients with EGFR-rich tumors that
might be especially sensitive to treatment with erlotinib cannot be
supported by these data.
Conclusions: Selection or exclusion of NSCLC patients for erlo-
tinib therapy after failure of standard therapy for advanced or
metastatic disease should not be based solely on EGFR protein
expression as determined by immunohistochemistry.
(J Thorac Oncol. 2006;1: 837–846)
The epidermal growth factor receptor (EGFR) pathway isinvolved in cell proliferation, metastasis, and angiogene-
sis, and components of this pathway have been implicated in
many different cancer types as a promoter of tumor growth.
Elevated levels of EGFR determined by immunohistochem-
istry (IHC) have been correlated with poor clinical outcomes
of patients with head and neck, ovarian, cervical, bladder, and
esophageal cancer, whereas more modest relationships have
been reported for gastric, breast, endometrial, and colorectal
cancers.1 The prognostic role of EGFR expression in non-
small cell lung cancer (NSCLC) is unclear. Some studies
have reported relationships between high expression of
EGFR and poor clinical outcomes,2–4 including a meta-
analysis of 16 studies.5 However, other studies have failed to
find any relationships.6–8
The emergence of therapies that specifically target the
EGFR pathway, either antibodies or small-molecule inhibi-
tors of the EGFR tyrosine kinase, raises questions about the
predictive utility of EGFR for patients with NSCLC who are
treated with these EGFR inhibitors. Most reported studies
have found no relationships between EGFR expression by
IHC and clinical outcomes of patients treated with gefinitib
(AstraZeneca, Wilmington, DE)9–13 or erlotinib (OSI Phar-
maceuticals, Inc., Melville, NY),14–16 although none of these
studies included an untreated control arm. Relationships with
gefitinib have been reported in two recent studies using
relatively high cutoffs to define EGFR positivity.17–18
The terms “prognostic” and “predictive” have been
used in numerous publications to describe relationships be-
tween biomarkers and clinical outcomes; however, these
terms are seldom defined and are often used interchangeably.
In this assessment, we will use the definitions proposed by
Clark19,20 and Hayes.21 A prognostic factor is a measurement
that is associated with clinical outcome in the absence of
therapy or with the application of a standard therapy that all
patients are likely to receive. It can be thought of as a measure
of the natural history of the disease. A control group from a
randomized clinical trial is an ideal setting for evaluating the
prognostic significance of a biomarker. A predictive factor is
a measurement that is associated with response or lack of
response to a particular therapy. Response can be defined
using any of the clinical endpoints commonly used in clinical
trials. A predictive factor implies a differential benefit from
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the therapy that depends on the status of the predictive
biomarker. In statistical terms, this constitutes an interaction
between treatment benefit and biomarker status that is best
evaluated in a randomized clinical trial with a control group.
National Institute of Canada Clinical Trials Group
(NCIC CTG) Study BR.21 was a randomized, placebo-con-
trolled study of erlotinib (Tarceva®, OSI Pharmaceuticals,
Inc., Melville, NY) versus placebo for the second- or third-
line treatment of patients with advanced NSCLC. The pla-
cebo control arm provided a unique opportunity to evaluate
the prognostic significance of EGFR expression by IHC in
these patients, and the randomization between placebo and
single-agent erlotinib permitted assessment of the predictive
significance of EGFR expression in this setting. Treatment
with single-agent erlotinib eliminates the confounding effects
of chemotherapy and/or radiotherapy that may be present
when EGFR inhibitors are combined with other treatment
modalities.
Evaluation of the clinical significance of EGFR expres-
sion by IHC has been complicated by the use of different
antibodies, different scoring systems, and different clinical
endpoints. In this report, we focus on one diagnostic kit
(Dako EGFR pharmDx™ kit) and one clinical outcome
(survival) from NCIC CTG Study BR.21 to determine an
optimal scoring system, including appropriate cutpoints, for
assessing the prognosis of patients with NSCLC and for
predicting treatment benefit from erlotinib.
MATERIALS AND METHODS
Erlotinib (Tarceva®, OSI-774)
Erlotinib is a potent, reversible, EGFR tyrosine kinase
inhibitor that is administered orally. It was approved in the
United States in November of 2004 for the treatment of
locally advanced or metastatic NSCLC after the failure of at
least one prior chemotherapy regimen, based on the results
from NCIC CTG Study BR.21 and supporting studies. The
recommended dosing regimen is 150 mg orally once daily on
a continuous schedule.21
Patients
NCIC CTG Study BR.21 has been previously de-
scribed.22 Briefly, 731 patients with incurable stage IIIB/IV
NSCLC after failure of at least one, but no more than two
prior regimens for advanced or metastatic disease were strat-
ified by center, performance status, best response to prior
therapy, number of prior regimens, and exposure to prior
platinum, and were randomized 2:1 to receive 150 mg daily
of erlotinib or placebo. The primary endpoint of the study
was overall survival. A total of 587 patients (80%) had died
at the time of database lock, and the median follow-up of
patients still alive was 15 months (range, 0.4–26 months).
Treatment with erlotinib produced a statistically significant
improvement in both survival and progression-free survival.
Assessment of EGFR status was not a requirement for study
participation. Submission of tumor samples was voluntary
and required a separate informed consent.
EGFR IHC Assays
Biopsy specimens were collected from patients who
gave informed consent and were stored as paraffin blocks or
unstained slides. These specimens were archival tumor sam-
ples and were usually obtained at the time of initial diagnosis.
Slides were prepared by personnel in the NCIC Tumor Bank
and were sent to LabCorp (Research Triangle Park, NC),
where EGFR protein expression was determined using the
Dako EGFR pharmDx™ IHC kits (DakoCytomation Califor-
nia Inc, Carpinteria, CA). Two pathologists trained to inter-
pret the Dako pharmDX staining and certified by Dako onsite
training interpreted the staining results. The majority of the
interpretations were performed by one of the pathologists, but
the other pathologist provided coverage when necessary.
Slides were sent with a masked identification number so that
all assays would be performed blinded to patient character-
istics, treatment assignment, and clinical outcome. Analyses
were batched when possible in groups of approximately 50
samples. Scoring was performed according to the manufac-
turer’s instructions: 1) assess the total percentage of tumor
cells showing membrane staining (any intensity) with EGFR
(0–100%) (proportion score, PS); 2) assess the highest inten-
sity of membrane staining in EGFR stained cells (0  no
staining, 1  weak staining, 2  moderate staining, 3
 strong staining) (intensity score, IS); 3) assess the percent-
age of cells displaying the highest intensity of membrane
staining (0–100%); 4) describe membrane staining as pre-
dominantly complete or incomplete; and 5) assess the per-
centage of cytoplasmic staining observed (0–100%). End-
points 3, 4, and 5 were not evaluated as prognostic or
predictive factors in this study. Any and all areas of the tumor
were assessed for whether there was staining, whether the
staining was membrane staining, the intensity of the staining,
and the completeness of the staining. All staining runs were
accompanied by the cell-line control slide that is included
with the kit; in addition, each staining run had two additional
“tumor control” slides containing sections of formalin-fixed,
paraffin-embedded tumors that had been previously scored as
“0” and “1, weak” intensity. An assay was successful if
tumor was present in the section and if all of the controls
showed staining similar to the intended staining. Any section
that showed no staining of tumor cells and no internal control
positive staining was repeated. Any section that showed no
staining of tumor cells but had positive internal control
staining of benign structures (e.g., perineural locations) was
interpreted, with a comment indicating the presence of inter-
nal control staining.23
There is no consensus in the literature about how to
summarize these scoring assessments into a single determi-
nation of EGFR protein expression status as EGFR positive
or EGFR negative. The Dako Cytomation EGFR pharmDx
Interpretation Manual suggests that any membrane staining
should be considered positive.24 The statistical analysis plan
for NCIC CTG Study BR.21 prespecified membrane staining
in at least 10% of tumor cells for a sample to be declared
EGFR positive, and clinical correlations have been published
using this definition.25 Some studies have focused on the
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intensity of the staining,14 and others have used a hybrid of
the PS and the intensity.17,18
Statistical Methods
Three measures of EGFR positivity were evaluated: a)
PS, defined as the percentage of tumor cells stained (any
intensity) with EGFR; b) IS, defined as the highest intensity
of membrane staining in EGFR-stained cells (0  no stain-
ing, 1  weak staining, 2  moderate staining, 3 
strong staining); c) hybrid score (HS), defined as PS multi-
plied by (IS 1), yielding a HS ranging from 0 to 400.17
Survival benefit was summarized using the hazard
ratio, defined as the ratio of the death rates among patients
still alive in two subsets at each point in time. Under the
assumption of proportional hazards, the ratio is the same at
each point in time. Hazard ratios were estimated from Cox
proportional hazards models as implemented in PROC
PHREG in SAS, Version 8.2 (Cary, NC).
To assess the prognostic significance of each of these
EGFR scores, only patients from the placebo arm of NCIC
CTG Study BR.21 were included in the analyses. A search for
the “optimal” cutpoint was performed by classifying patients
as high or low EGFR using every possible cutpoint for each
of the three measures, creating a univariate Cox model for
each cutpoint, and calculating the resulting hazard ratio for
death for patients with EGFR-positive tumors relative to
patients with EGFR-negative tumors. “Optimal” was defined
as the cutpoint that yielded the smallest p value from a
log-rank test. Because several published studies assessed the
prognostic significance of EGFR expression in patients uni-
formly treated with an EGFR inhibitor, similar analyses were
performed using only patients in the erlotinib arm.
To assess the predictive significance of each of these
EGFR scores, all patients with evaluable EGFR assays were
included in the analyses. Separate Cox models were con-
structed for EGFR-positive patients and for EGFR-negative
patients to estimate treatment effects of erlotinib relative to
placebo for each cutpoint of each EGFR measure. A series of
Cox models were then created that included factors for
treatment (erlotinib versus placebo), EGFR status (high ver-
sus low), and the interaction between treatment and EGFR
status. The p values associated with the Wald statistic for the
interaction term from the full models containing all three
factors and the corresponding hazard ratio for death were
evaluated to determine whether any cutpoints produced sta-
tistically significant interactions indicative of differential pre-
dictive effects depending on EGFR status.
All statistical analyses were performed by the sponsor
of the clinical trial and were confirmed by NCIC CTG.
RESULTS
Tumor samples from 375 patients were sent to the
central laboratory for EGFR assays by IHC, and evaluable
assay results were obtained for 325 patients (87%). Among
the 50 patients with unevaluable results, 38 (76%) had insuf-
ficient tumor cells in their tumor sample, six (12%) had
extensive necrosis, three (6%) had inadequate control stain-
ing, two (4%) had poor tumor preservation, and one (2%) had
a broken slide.
Tumors from 229 (70%) of the 325 patients with
evaluable assay results had some EGFR staining. Patient
demographics, tumor characteristics, and treatment outcomes
for patients with or without evaluable EGFR results are
displayed in Table 1. Relatively few Asian patients provided
tumor samples for EGFR evaluation. Among patients with
known EGFR protein expression status, there were fewer
patients with Eastern Cooperative Oncology Group perfor-
mance status 0 or 1, and more with two or more prior
therapies, although fewer received taxanes. There was a
greater incidence of nonprogression (complete response/par-
tial response/stable disease) as the best response to prior
therapy, and a longer time between diagnosis and random-
ization on NCIC CTG Study BR.21 was found for patients
with EGFR results compared with patients without results.
Despite these imbalances, no significant differences in sur-
vival were observed between patients with or without EGFR
results. Most importantly, the benefit from erlotinib was
similar in the two subsets.
Prognostic Significance
A total of 115 patients in the placebo arm had evaluable
EGFR protein expression results by IHC, and 99 had died at
the time of database lock. Univariate Cox models with EGFR
results expressed as continuous variables produced hazard
ratios of death greater than 1.0 (indicating worse survival for
patients with increasing levels of EGFR) for each of the
EGFR measures (HR  1.008, 1.285, and 1.002 for PS, IS,
TABLE 1. Demographic and Tumor Characteristics of
Patients with and without Epidermal Growth Factor Receptor
(EGFR) Expression Status
Known EGFR Unknown EGFR
Factor (n  325) (n  406) p value
Erlotinib 65% 68% 0.30
Male 65% 65% 0.88
Asian 6% 17% 0.0001
Never smoked 22% 21% 0.71
Adenocarcinoma 50% 50% 0.82
ECOG performance
status 0-1
62% 70% 0.041
CR/PR/SD as best
response to prior
therapy
83% 76% 0.022
2 prior regimens 57% 45% 0.0014
Prior platinum 93% 93% 1.00
Prior taxane 32% 40% 0.037
Median age (yr) 61 61 0.68
Median months since
diagnosis
14 12 0.015
Median survival for
erlotinib (months)
7.1 6.3 0.96
Median survival for
placebo (months)
4.1 5.5 0.87
Hazard ratio for death 0.76 0.77
(p  0.030) (p  0.031)
ECOG, Eastern Cooperative Oncology Group; CR/PR/SD, complete response/
partial response/stable disease.
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and HS, respectively), but none were statistically significant
(p 0.5587, 0.3241, and 0.4702, respectively). Hazard ratios
of death for EGFR-positive patients relative to EGFR-nega-
tive patients and corresponding p values for every possible
cutpoint are displayed in Table 2 for each EGFR measure.
Hazard ratios were greater than 1.0 for every cutpoint for
each EGFR measure, but none were statistically significant
(p  0.20), even without adjustments for multiple-hypothesis
testing. Patients with very high EGFR expression did not
appear to have worse survival than patients with lower EGFR
expression. The largest hazard ratios were produced when
any staining was considered EGFR positive.
A total of 210 patients in the erlotinib arm had evalu-
able EGFR protein expression results, and 164 had died at the
time of database lock. Univariate Cox models with EGFR
results expressed as continuous variables produced hazard
ratios very close to 1.0 for each of the EGFR measures
(HR  1.000, 1.001, and 1.000 for PS, IS, and HS, respec-
tively), and none were statistically significant (p  0.9812,
0.9908, and 0.8782, respectively). Hazard ratios and corre-
sponding p values for every possible cutpoint are displayed in
Table 2 for each EGFR measure. Hazard ratios were numer-
ically less than 1.0 only for low cutpoints for each EGFR
measure, but none were statistically significant (p  0.20),
even without adjustments for multiple-hypothesis testing.
Patients with very high EGFR expression had slightly worse
survival than patients with lower EGFR expression, as evi-
denced by hazard ratios greater than 1.0.
These results suggest that the prognostic significance of
EGFR expression by IHC for patients with advanced NSCLC
is modest at best. After failure of first-line chemotherapy,
patients with EGFR-positive tumors had slightly worse sur-
vival than patients with EGFR-negative tumors if they received
no additional therapy. If these patients received erlotinib, sur-
vival was slightly better for patients with EGFR-positive
tumors, provided that EGFR positivity is defined using a
relatively low cutpoint. However, the differences in survival
were not statistically different for any cutpoint for any of the
three measures of EGFR expression.
Predictive Significance
Hazard ratios for death of patients on the erlotinib arm
relative to patients on the placebo arm and corresponding p
values for patients with EGFR-positive tumors using every
possible cutpoint are displayed in Table 3 for each EGFR
measure. These hazard ratios were generally less than 1.0,
regardless of the cutpoint used to define EGFR positivity,
indicating a survival benefit for patients with EGFR-positive
tumors who received erlotinib compared with placebo. Haz-
ard ratios that were statistically significantly less than 1.0,
with unadjusted p values less than 0.05, were produced by PS
cutpoints between 0 and 20%, IS cutpoints of 1 or 2, and
HS cutpoints between 0 and 40. Hazard ratios produced by
higher cutpoints were not statistically significant, indicating
that patients with very high EGFR expression did not expe-
rience enhanced survival benefit from erlotinib treatment
compared with placebo. In fact, the hazard ratios tended to
increase (indicating less treatment benefit) with increasing
EGFR expression.
Hazard ratios and corresponding p values for patients
with EGFR-negative tumors using every possible cutpoint are
also displayed in Table 3 for each EGFR measure. These
hazard ratios were also generally less than 1.0 regardless of
the cutpoint used to define EGFR positivity, indicating a
survival benefit for patients with EGFR-negative tumors who
received erlotinib compared with placebo. Hazard ratios that
were statistically significantly less than 1.0, with unadjusted
p values  0.05, were produced when relatively high cutoffs
TABLE 2A. Cutpoint Analysis to Assess Prognostic Effect of Proportion Score (PS)
Placebo arm (n  115) Erlotinib arm (n  210)
PS cutpoint % positive
HR EGFR:
EGFR 95% CI
Log rank
p value % positive
HR EGFR:
EGFR 95% CI
Log rank
p value
1% 71 1.317 0.840–2.066 0.2272 70 0.955 0.683–1.335 0.7877
2% 70 1.317 0.849–2.045 0.2170 65 0.839 0.608–1.158 0.2854
5% 67 1.249 0.815–1.916 0.3052 63 0.879 0.639–1.210 0.4292
10% 58 1.166 0.778–1.748 0.4564 56 0.868 0.636–1.184 0.3705
15% 46 1.137 0.763–1.695 0.5267 47 0.877 0.645–1.192 0.4017
20% 46 1.137 0.763–1.695 0.5267 45 0.910 0.669–1.238 0.5465
25% 40 1.026 0.683–1.543 0.9013 38 0.874 0.637–1.198 0.4019
30% 40 1.026 0.683–1.543 0.9013 36 0.952 0.694–1.308 0.7631
40% 31 1.048 0.683–1.606 0.8325 32 1.035 0.747–1.434 0.8360
50% 29 1.081 0.696–1.678 0.7286 30 1.077 0.774–1.498 0.6591
60% 23 1.087 0.675–1.749 0.7313 24 1.119 0.787–1.591 0.5325
70% 17 1.191 0.713–1.989 0.5041 20 1.114 0.762–1.627 0.5775
75% 13 1.238 0.701–2.187 0.4607 17 1.024 0.677–1.549 0.9092
80% 12 1.159 0.644–2.083 0.6217 15 1.133 0.745–1.724 0.5598
85% 10 1.254 0.667–2.357 0.4812 12 0.997 0.618–1.610 0.9906
90% 9 1.146 0.594–2.213 0.6837 12 0.997 0.618–1.610 0.9906
95% 5 1.075 0.466–2.482 0.8653 7 1.139 0.632–2.054 0.6647
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were used. Because use of high cutoffs to define EGFR
positivity produces subsets of EGFR-negative patients whose
tumors contain relatively high levels of EGFR expression,
this finding should not be surprising. When low cutoffs were
used, hazard ratios for EGFR-negative patients increased and
were not significantly different than 1.0.
Hazard ratios for patients with EGFR-positive tumors
by IHC tended to be less than those for patients with EGFR-
negative tumors, suggesting greater benefit from erlotinib
among patients with EGFR-positive tumors. To formally
compare hazard ratios between EGFR-positive and EGFR-
negative patients, statistical tests of interactions between
EGFR status and treatment were performed. p values from
these interaction tests are displayed in the last column of
Table 3. None of the interaction p values were statistically
significant. Use of any staining to define EGFR positivity
produced hazard ratios and interaction p values that were
about the same as those produced when 10% staining was
TABLE 2B. Cutpoint Analysis to Assess Prognostic Effect of Intensity Score (IS)
Placebo arm (n  115) Erlotinib arm (n  210)
IS cutpoint % positive
HR EGFR:
EGFR 95% CI
Log rank
p value % positive
HR EGFR:
EGFR 95% CI
Log rank
p value
1 71 1.317 0.840–2.066 0.2272 70 0.955 0.683–1.335 0.7877
2 50 1.099 0.739–1.635 0.6408 46 0.920 0.676–1.251 0.5944
3 28 1.209 0.785–1.861 0.3874 22 1.204 0.837–1.733 0.3174
TABLE 2C. Cutpoint Analysis to Assess Prognostic Effect of Hybrid Score (HS)
Placebo arm (n  115) Erlotinib arm (n  210)
HS cutpoint % positive
HR EGFR:
EGFR 95% CI
Log rank
p value % positive
HR EGFR:
EGFR 95% CI
Log rank
p value
2 71 1.317 0.840–2.066 0.2272 70 0.955 0.683–1.335 0.7877
3 70 1.317 0.849–2.045 0.2170 66 0.810 0.586–1.118 0.1999
4 70 1.317 0.849–2.045 0.2170 65 0.839 0.608–1.158 0.2854
6 68 1.226 0.797–1.886 0.3522 63 0.879 0.639–1.210 0.4292
10 67 1.249 0.815–1.916 0.3052 63 0.879 0.639–1.210 0.4292
15 61 1.147 0.761–1.729 0.5101 57 0.900 0.659–1.228 0.5063
20 60 1.099 0.731–1.652 0.6500 56 0.868 0.636–1.184 0.3705
30 53 1.195 0.801–1.782 0.3802 50 0.862 0.634–1.172 0.3433
40 49 1.210 0.812–1.803 0.3462 46 0.898 0.660–1.221 0.4929
45 44 1.083 0.725–1.616 0.6967 44 0.935 0.687–1.272 0.6669
60 44 1.083 0.725–1.616 0.6967 44 0.968 0.711–1.318 0.8377
75 41 0.989 0.659–1.484 0.9573 39 0.973 0.712–1.330 0.8657
80 41 0.989 0.659–1.484 0.9573 38 1.028 0.752–1.407 0.8606
90 37 0.963 0.636–1.457 0.8567 36 0.952 0.693–1.309 0.7638
100 35 1.009 0.664–1.534 0.9652 34 0.975 0.705–1.347 0.8770
120 33 0.993 0.649–1.518 0.9735 32 0.970 0.699–1.347 0.8562
140 27 1.184 0.758–1.849 0.4556 29 1.032 0.737–1.446 0.8543
150 27 1.184 0.758–1.849 0.4556 28 1.033 0.736–1.451 0.8504
160 25 1.285 0.818–2.017 0.2741 25 1.083 0.762–1.540 0.6557
180 24 1.289 0.816–2.035 0.2740 25 1.083 0.762–1.540 0.6557
200 22 1.347 0.842–2.155 0.2121 23 1.075 0.747–1.547 0.6975
210 19 1.287 0.786–2.109 0.3142 21 1.112 0.767–1.612 0.5759
225 17 1.297 0.776–2.169 0.3194 20 1.157 0.792–1.690 0.4510
240 17 1.230 0.727–2.080 0.4388 19 1.270 0.866–1.862 0.2219
270 12 1.193 0.664–2.144 0.5540 16 1.321 0.873–1.998 0.1880
280 12 1.193 0.664–2.144 0.5540 15 1.276 0.838–1.942 0.2561
320 9 1.209 0.626–2.337 0.5703 13 1.059 0.669–1.675 0.8079
340 9 1.209 0.626–2.337 0.5703 11 0.907 0.548–1.499 0.7019
360 8 1.096 0.550–2.185 0.7943 11 0.907 0.548–1.499 0.7019
380 4 0.989 0.397–2.466 0.9813 7 1.069 0.579–1.974 0.8313
EGFR, epidermal growth factor receptor; HR, hazard ratio for death; CI, confidence interval.
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used to define EGFR positivity (p  0.2616 and 0.2503,
respectively). Both of these definitions seem to be superior to
high HS cutoffs, such as HS  200 as proposed by Hirsch17
and Cappuzzo.18
These results suggest that the treatment benefits from
erlotinib relative to placebo are not significantly different for
patients with EGFR-positive and EGFR-negative tumors as
determined by IHC, regardless of the EGFR measure or the
cutoff used to define EGFR positivity.
Despite the nonsignificant interaction between EGFR
protein expression status and treatment, the HR for EGFR-
negative patients, using 10% staining to define EGFR
positivity, was 0.926 (p  0.6965), which highly suggests a
lack of treatment benefit in this subset of patients. However,
there is evidence that some patients with apparently EGFR-
negative tumors did benefit from erlotinib treatment (Table
4). For example, the hazard ratio for patients with Eastern
Cooperative Oncology Group performance status 0 or 1 who
had received only one previous chemotherapy regimen was
0.47 (p  0.02). Median survivals were 9.0 and 5.3 months,
respectively, for the erlotinib and placebo arms. This subset
comprised 35% of all patients with tumors with staining in
less than 10% of tumor cells. Among patients with tumors
with staining in less than 10% of tumor cells who received
erlotinib, 72% experienced rash. The median survival of these
patients was 8.6 months, compared with 6.2 months for
patients with EGFR-negative tumors who received placebo
(HR  0.68, p  0.08). Therefore, EGFR-negativity as
determined by IHC, as a single biomarker, does not neces-
sarily predict failure to benefit from treatment with erlotinib.
DISCUSSION
The majority of publications that describe the clinical
utility of EGFR status do not contain a control group from a
randomized clinical trial. Therefore, statements about the
clinical significance of EGFR status are confounded by prog-
nostic significance and predictive significance as defined in
this study. NCIC CTG Study BR.21 provided an opportunity
to thoroughly assess both the prognostic significance of
EGFR expression by IHC and its ability to differentially
predict survival of patients with advanced NSCLC who
received either erlotinib or placebo.
In this study, EGFR protein expression by IHC was not
a significant prognostic factor for survival of patients in the
placebo arm. Despite a suggestion that patients with EGFR-
positive tumors had slightly worse survival than patients with
TABLE 3A. Cutpoint Analysis to Assess Predictive Effect of Proportion Score (PS)
EGFR positive EGFR negative
PS cutpoint % positive
HR erlotinib:
placebo
p value for
treatment
HR erlotinib:
placebo
p value for
treatment
p value for
interaction
1% 70 0.697 0.0158 0.957 0.8579 0.2616
2% 67 0.665 0.0079 1.043 0.8537 0.1097
5% 65 0.681 0.0142 0.977 0.9171 0.2003
10% 57 0.678 0.0216 0.926 0.6965 0.2503
15% 46 0.656 0.0241 0.883 0.4766 0.2839
20% 46 0.667 0.0314 0.864 0.4012 0.3525
25% 38 0.696 0.0775 0.820 0.2243 0.5349
30% 38 0.728 0.1234 0.793 0.1551 0.7604
40% 32 0.766 0.2389 0.760 0.0743 0.9598
50% 30 0.779 0.2903 0.756 0.0652 0.9438
60% 24 0.823 0.4661 0.752 0.0496 0.8843
70% 19 0.743 0.3149 0.769 0.0630 0.8034
75% 15 0.684 0.2589 0.780 0.0714 0.5678
80% 14 0.795 0.5086 0.761 0.0466 0.9170
85% 11 0.655 0.2729 0.779 0.0638 0.5646
90% 11 0.713 0.3966 0.772 0.0545 0.7191
95% 6 1.108 0.8629 0.753 0.0307 0.8376
TABLE 3B. Cutpoint Analysis to Assess Predictive Effect of Intensity Score (IS)
EGFR positive EGFR negative
IS cutpoint % positive
HR erlotinib:
placebo
p value for
treatment
HR erlotinib:
placebo
p value for
treatment
p value for
interaction
1 70 0.697 0.0158 0.957 0.8579 0.2616
2 47 0.699 0.0499 0.843 0.3401 0.4449
3 24 0.783 0.3190 0.771 0.0818 0.9895
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EGFR-negative tumors, there were no cutpoints for any of the
three EGFR measures that produced a statistically significant
separation with respect to survival between these subsets of
patients. Similarly, in the erlotinib arm, EGFR protein ex-
pression by IHC was not a significant prognostic factor for
survival despite a suggestion that patients with EGFR-posi-
tive tumors had slightly better survival. There may, however,
be a selection bias in any clinical trial that includes patients
who have received prior therapy for their disease. It is
possible that EGFR status is a strong prognostic factor for
patients with newly diagnosed NSCLC and that patients with
EGFR-positive tumors died earlier or were more likely to
have been excluded from participation in NCIC CTG Study
BR.21. Nevertheless, among patients who were enrolled in
TABLE 3C. Cutpoint Analysis to Assess Predictive Effect of Hybrid Score (HS)
EGFR positive EGFR negative
HS cutpoint % positive
HR erlotinib:
placebo
p value for
treatment
HR erlotinib:
placebo
p value for
treatment
p value for
interaction
2 70 0.697 0.0158 0.957 0.8579 0.2616
3 67 0.658 0.0062 1.061 0.7982 0.0848
4 67 0.665 0.0079 1.043 0.8537 0.1097
6 65 0.686 0.0156 0.963 0.8683 0.2282
10 65 0.681 0.0142 0.977 0.9171 0.2003
15 58 0.706 0.0354 0.910 0.6422 0.3640
20 57 0.706 0.0369 0.903 0.6103 0.3773
30 51 0.640 0.0118 0.926 0.6797 0.1716
40 47 0.644 0.0166 0.896 0.5387 0.2206
45 44 0.697 0.0593 0.832 0.2864 0.5309
60 44 0.709 0.0730 0.820 0.2487 0.6215
75 40 0.753 0.1592 0.782 0.1378 0.9146
80 39 0.775 0.2077 0.766 0.1071 0.9283
90 36 0.763 0.2017 0.774 0.1095 0.9537
100 34 0.758 0.2052 0.766 0.0895 0.9732
120 32 0.772 0.2522 0.760 0.0757 0.9711
140 28 0.704 0.1459 0.782 0.1010 0.6707
150 28 0.707 0.1525 0.781 0.0993 0.6754
160 25 0.678 0.1206 0.791 0.1118 0.5607
180 25 0.681 0.1298 0.789 0.1071 0.5604
200 22 0.637 0.0887 0.797 0.1186 0.4382
210 21 0.692 0.1926 0.781 0.0831 0.6117
225 19 0.729 0.2849 0.770 0.0641 0.7184
240 18 0.822 0.5172 0.750 0.0412 0.9301
270 14 0.859 0.6566 0.743 0.0303 0.7670
280 14 0.836 0.6034 0.747 0.0338 0.8412
320 11 0.726 0.4151 0.769 0.0510 0.7456
340 10 0.635 0.2644 0.783 0.0679 0.4961
360 10 0.697 0.3925 0.776 0.0581 0.6545
380 6 1.278 0.7172 0.752 0.0297 0.8056
EGFR, epidermal growth factor receptor; HR, hazard ratio for death.
TABLE 4. Subsets of Patients with EGFR-Negative Tumors
(Staining  10%)
Subset
Percentage of patients with
staining < 10% HR p value
Second line 48% 0.63 0.09
ECOG PS 0 or 1 72% 0.80 0.35
ECOG PS 0 or 1,
second line
35% 0.47 0.03
Patients with rash 72% of Tarceva-treated patients
with staining  10%
0.68 0.08
Second line, patients who received only one previous chemotherapy regimen;
ECOG PS, Eastern Cooperative Oncology Group performance status.
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this clinical trial, EGFR protein expression by IHC was not a
strong prognostic factor.
One might expect that patients with EGFR-positive tu-
mors should derive greater benefit from therapy with EGFR
inhibitors compared with patients with EGFR-negative tumors.
Visually, this appeared to the case in NCIC CTG Study BR.21,
where the hazard ratio for death for patients with EGFR-positive
tumors was 0.678 (p 0.0216), compared with 0.926 (p 0.6965)
for patients with EGFR-negative tumors, using the predefined
definition of EGFR positivity of staining in 10% of tumor cells.
Nevertheless, a formal comparison of these hazard ratios indicated
that they were not statistically significantly different (p 0.2503).
Evaluation of different measures of EGFR protein ex-
pression by IHC and different cutpoints for defining EGFR
positivity revealed that EGFR protein expression was a weak
predictive factor for survival benefit from erlotinib in this
study. The hazard ratios for death were generally lower
(indicating more treatment benefit) for patients with EGFR-
positive tumors compared with patients with EGFR-negative
tumors; nevertheless, none of the interactions between EGFR
status and treatment benefit were statistically significant. Use
of very high cutpoints to define patients with EGFR-rich
tumors that might be especially sensitive to treatment with
erlotinib cannot be supported by these data. On the contrary,
because patients with even low levels of EGFR protein
expression may derive some benefit from erlotinib, if a
cutpoint must be used, it should be as low as possible. Thus,
these data support the recommendation supplied with Dako
EGFR pharmDx™ kits (DakoCytomation California Inc,
Carpinteria, CA) that any membrane staining should be
interpreted as EGFR positive.
There are several possible explanations for lack of
correlations between EGFR protein expression by IHC and
clinical outcomes. These include false-negative results attrib-
utable to a lack of sensitivity in the detection system, heter-
ogeneity of EGFR expression within the tumor, and specific
mutations that might mediate responses to the tyrosine kinase
inhibitors.26 Most of the tumor samples in this study were
obtained at the time of diagnosis, and all patients received
and eventually failed intervening first-line therapy. It is not
clear whether EGFR protein expression as determined by
IHC is affected by such therapy. Emerging data indicate that
EGFR protein expression in primary tumors may not corre-
late with EGFR expression in metastatic sites, at least in
colorectal tumors.27 In addition, expression of EGFR may
have different consequences depending on histological sub-
type and coexpression of TGF and ras genotype.28 It is
possible that some of the tumors were not adequate to
accurately reflect the status of protein expression by IHC.
Although all tumor samples were visually examined before
they were assayed by IHC, a specific protocol that included
requirements for minimum numbers of cells evaluated, min-
imum numbers of blocks/sections to be evaluated, type and
duration of fixation, and site of biopsy was not used. Clearly,
if a sample is inadequate, no molecular test will give infor-
mative results, regardless of how good or relevant the mea-
sured endpoint might be. Thus, the failure to find statistically
significant relationships between EGFR protein expression
and survival might be attributable to the quality of the
samples and/or the sensitivity of the assay.
It is also possible that the relatively modest sample size
of 325 patients with evaluable EGFR protein expression
results lacked sufficient statistical power to detect meaningful
prognostic or predictive relationships. Nevertheless, given the
multiplicity of statistical tests that were performed, one might
have expected a few cutpoints to have demonstrated statisti-
cal significance by chance alone. There is a considerable
literature that warns of overinterpretation of results from
searches for “optimal” cutpoints, with suggestions to adjust p
values to minimize the chances of falsely claiming statistical
significance.29,30 The p values that are reported in Tables 2
and 3 are undoubtedly overly optimistic and should be in-
flated before they can be properly interpreted.
Comparisons across studies are difficult because differ-
ent EGFR antibodies, preparation regimens, and scoring sys-
tems could contribute to discrepancies between studies. Vari-
ations in fixatives and storage time of tissue sections also can
impact the interpretation of assay results.31
Cetuximab (ImClone Systems, Inc., New York, NY) is
a monoclonal antibody that targets the extracellular domain
of EGFR. It is approved for the treatment of advanced
colorectal cancer for patients with tumors that express EGFR
as measured by the same Dako EGFR pharmDx kits used in
NCIC CTG Study BR.21. Recently, clinical activity has been
demonstrated in patients with colorectal cancer whose tumors
were scored as EGFR negative by IHC.32 These tumors may
well have expressed EGFR protein that was not detected by
the assay. The authors concluded that selection or exclusion
of patients for cetuximab therapy on the basis of currently
available EGFR IHC tests is not warranted.
Based on the results of the current study, a similar
conclusion might be appropriate for erlotinib and patients
with NSCLC. Although the entire subset of patients with
EGFR-negative tumors as determined by IHC did not seem to
benefit from treatment with erlotinib, relatively large subsets
of patients with apparently EGFR-negative tumors did benefit
in this study. This suggests that additional factors should be
taken into account before treatment decisions can be made. It
is possible that EGFR protein expression is truly an important
prognostic and predictive biomarker but that current tech-
niques for performing IHC testing are not capable of discrim-
inating in this regard.
It has been suggested that total EGFR expressed on the
cell membrane may not be the most relevant biomarker for
predicting responses to EGFR tyrosine kinase inhibitors.
Because the effects of EGFR activation on the cell are
mediated by downstream signal-transduction cascades, in-
cluding the PI3K/Akt, RAS/Raf/Erk, and Jak/STAT path-
ways, EGFR downstream molecules have also been investi-
gated.33–37 Results of these investigations have generally been
disappointing in that relationships between these biomarkers
and clinical outcomes have not been consistently observed.
More recently, amplification or high polysomy of the EGFR
gene has shown promise as a predictor of clinical benefit from
EGFR inhibitors,13,17,18,25 and several studies are underway to
confirm these results.
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One might anticipate that EGFR protein expression
determined by IHC in combination with other biomarkers in
the EGFR pathway might eventually provide a means for
identifying patients who should or should not be considered
candidates for treatment with EGFR inhibitors. This may be
particularly important in earlier stages of disease, where
first-line treatment and adjuvant therapy are commonly ad-
ministered. While we wait for these results, it might be
prudent to adopt a more pragmatic approach for patient
selection in the second- and third-line settings.
Treatment-related rash has been associated with rela-
tively long survival in a number of studies involving EGFR
inhibitors. In NCIC CTG Study BR.21, the median time to
develop rash was 8 days, and 90% of patients who experi-
enced rash did so within 25 days. Because 72% of the patients
with EGFR-negative tumors by IHC who received erlotinib in
NCIC CTG Study BR.21 experienced rash, and their median
survival was 8.6 months compared with a median of 5.3
months for EGFR-negative patients who received placebo, it
might be reasonable to consider all patients with incurable
stage IIIB/IV NSCLC who have failed standard therapy for
advanced or metastatic disease to be candidates for treatment
with erlotinib, regardless of their EGFR protein expression
status by IHC. Cumulative evidence from this and other
studies suggests that patients who do not experience rash
within 3 to 4 weeks may have poor clinical outcomes. Studies
exploring this further are being conducted and include testing
of dose intensification in patients who do not experience rash.
Such patients may be candidates for alternative therapies.
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